Protective efficacy of recombinant exotoxin A — flagellin fusion protein against Pseudomonas aeruginosa infection

Canadian Journal of Microbiology

Volumn 61, Issue 1, 2014, Pages 60-64

  Farajnia, Safar ^a   Peerayeh, Shahin Najar ^b   Tanomand, Asghar ^b,c   Majidi, Jafar ^c   Goudarzi, Gholamreza ^d   Naghili, Behrooz ^a   Rahbarnia, Leila ^e  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TARBIAT MODARES UNIVERSITY   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d LORESTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Exotoxin A flagellin; Fusion fusion protein; Pseudomonas aeruginosa; Vaccine candidate

Indexed keywords

BACTERIAL VACCINE; EXOTOXIN A FLAGELLIN FUSION PROTEIN; HYBRID PROTEIN; IMMUNOGLOBULIN G ANTIBODY; NITRILOTRIACETATE NICKEL; PROTECTIVE AGENT; UNCLASSIFIED DRUG; BACTERIAL PROTEIN; BACTERIUM ANTIBODY; EXOTOXIN; FLAGELLIN; RECOMBINANT PROTEIN;

ANTIBODY; BACTERIAL DISEASE; BIOASSAY; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNIZATION; PROTEIN; RECOMBINATION; RODENT; TOXIN; VACCINE;

AFFINITY CHROMATOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; BACTERIAL IMMUNITY; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; DRUG PURIFICATION; DRUG SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; EVALUATION STUDY; FEMALE; IMMUNE RESPONSE; LD 50; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; VACCINATION; ANIMAL; BAGG ALBINO MOUSE; GENETICS; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOLOGY; MICROBIOLOGY; PHYSIOLOGY; PSEUDOMONAS INFECTIONS;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; MUS; PSEUDOMONAS AERUGINOSA;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; BACTERIAL VACCINES; EXOTOXINS; FEMALE; FLAGELLIN; HUMANS; IMMUNITY, HUMORAL; IMMUNIZATION; MICE; MICE, INBRED BALB C; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RECOMBINANT PROTEINS; VACCINATION;

EID: 84920697337     PISSN: 00084166     EISSN: 14803275     Source Type: Journal    
DOI: 10.1139/cjm-2014-0501     Document Type: Article

References (24)

1. Barnea, Y., Carmeli, Y., Neville, L., Kahel-Reifer, H., Eren, R., Dagan, S., et al. 2009. Therapy with anti-flagellin a monoclonal antibody limits Pseudomonas aeruginosa invasiveness in a mouse burn wound sepsis model. Burns, 35: 390–396. doi: 10.1016/j.burns.2008.08.014. PMID:18951715.
2. Campodonico, V., Llosa, N., Grout, M., Doring, G., Maira-Litran, T., and Pier, G. 2010. Evaluation of flagella and flagellin of Pseudomonas aeruginosa as Vaccines. Infect. Immun. 78: 746–755. doi:10.1128/IAI.00806-09. PMID:19995892.
3. Chen, T.Y., and Shang, H.F. 1999. Recombinant protein composed of Pseudomonas exotoxin A, outer membrane proteins I and F as vaccine against P. aeruginosa infection. Appl. Microbiol. Biotechnol. 52: 524–533. doi:10.1007/s002530051555. PMID:10570800.
4. Cryz, S.J., Jr., Furer, E., Sadoff, J.C., Germanier, R., Pastan, I., Willingham, M.C., et al. 1987. Use of Pseudomonas aeruginosa toxin A in the construction of conjugate vaccines and immunotoxins. Rev. Infect. Dis. 9(Supplement): S644–S649. doi:10.1093/clinids/9.Supplement_5.S644. PMID:3120274.
5. Cryz, S.J., Furer, E., and Que, U.J. 1991. Synthesis and charactization of a Pseudomonas aeruginosa alginate-toxin a conjugate vaccine. Infect. Immun. 59: 45–50. PMID:1898901.
6. Denis-Mize, K.S., and Price, B.M. 2000. Analysis of immunization with DNA encoding Pseudomonas aeruginosa exotoxin A. FEMS Immunol. Med. Microbiol. 27: 147–154. doi:10.1111/j.1574-695X.2000.tb01425.x. PMID:10640610.
7. Doring, G., and Pierb, G. 2008. Vaccines and immunotherapy against Pseudomonas aeruginosa. Vaccine, 26: 1011–1024. doi:10.1016/j.vaccine.2007.12.007. PMID: 18242792.
8. Doring, G., Meisne, C., and Stern, M. 2007. A double-blind randomized placebocontrolled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients. Proc. Natl. Acad. Sci. U.S.A. 104: 11020–11025. doi:10.1073/ pnas.0702403104. PMID:17585011.
9. Farajnia, S., Rahbarnia, L., Maleki Zanjani, B., Alimohammadian, M.H., Abdoli Oskoee, S., Behpajooh, A., et al. 2011. Molecular cloning and characterization of P4 nuclease from Leishmania infantum. Enzyme Res: 1–6. doi:10. 4061/2011/970983. PMID:21755045.
10. Goudarzi, G., Sattari, M., Roudkenar, M.H., Montajabi-Niyat, M., Zavaran-Hosseini, A., and Mosavi-Hosseini, K. 2009. Cloning, expression, purification, and characterization of recombinant flagellin isolated from Pseudomonas aeruginosa. Biotechnol. Lett. 31: 1353–1360. doi:10.1007/s10529-009-0026-1. PMID:19466558.
11. Heckman, K., and Pease, L. 2007. Gene splicing and mutagenesis by PCR-driven overlap extension. Nat. Protoc. 2: 924–932. doi:10.1038/nprot.2007.132. PMID: 17446874.
12. Hertle, R., Mrsny, R., and Fitzgerald, D. 2001. Dual-function vaccine for Pseudomonas aeruginosa: characterization of chimeric exotoxin A-pilin protein. Infect Immun. 69: 6962–6969. doi:10.1128/IAI.69.11.6962-6969.2001. PMID:11598071.
13. Kamei, A., Coutinho-Sledge, Y.S., Goldberg, J.B., Priebe, G.P., and Pier, G.B. 2011. Mucosal vaccination with a multivalent, live-attenuated vaccine induces multifactorial immunity against Pseudomonas aeruginosa acute lung infection. Infect Immun. 79: 1289–1299. doi:10.1128/IAI.01139-10. PMID:21149583.
14. Kashef, N., Beehzadian-Nejad, Q., Najar-Peerayeh, S., Mousavi-Hosseini, K., Moazzeni, M., and Esmaeeli, G. 2006. Synthesis and characterization of Pseudomonas aeruginosa alginate-tetanus toxoid conjugate. J. Med. Microbiol. 55: 1441–1446. doi:10.1099/jmm.0.46696-0. PMID:17005795.
15. Manafi, A., Kohanteb, J., Mehrabani, D., Japoni, A., Amini, M., Naghmachi, M., et al. 2009. Active immunization using exotoxin A confers protection against Pseudomonas aeruginosa infection in a mouse burn model. BMC Microbiol. 9: 23–227. doi:10.1186/1471-2180-9-23. PMID:19183501.
16. Matsumoto, T., Tateda, K., Miyazaki, S., Furuya, N., Ohno A, Ishii, Y., et al. 1999. Effect of antiflagellar human monoclonal antibody on gut-derived Pseudomonas aeruginosa sepsis in mice. Clin. Diagn. Lab. Immunol. 6: 537–541. PMID: 10391858.
17. Neville, L., Barnea, Y., Hammer-Munz, O., Gur, E., Kuzmenko, B., Kahel-Raifer, H., et al. 2005. Antibody raised against N-terminal pseudomonas aeruginosa flagellin prevent mortality in lethal murine models of infection. Int. J. Mol. Med. 16: 165–171. doi:10.3892/ijmm.16.1.165. PMID:15942694.
18. Nilsson, E., Amini, A., Wretlind, B., and Larsson, A. 2007. Pseudomonas aeruginosa infections are prevented in cystic fibrosis patients by avian antibodies binding Pseudomonas aeruginosa flagellin. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 856: 75–80. doi:10.1016/j.jchromb.2007.05.029. PMID:17581799.
19. Reed, L., and Muench, H.A. 1938. A simple method for estimating fifty percent end points. Am. J. Epidemiol. 27: 493–497.
20. Shiau, W.J., Tang, K.T., Shin, L.Y., Tai, C., Sung, Y.Y., Huang, L.J., et al. 2001. Mice immunized with DNA encoding a modified Pseudomonas aeruginosa exotoxin A develop protective immunity against exotoxin intoxication. Vaccine, 19: 1106–1112. doi:10.1016/S0264-410X(00)00335-2. PMID:11137245.
21. Tanomand, A., Farajnia, S., Najar Peerayeh, S., and Majidi, J. 2012. Cloning, expression and characterization of recombinant exotoxin A-flagellin fusion protein as a new vaccine candidate against Pseudomonas aeruginosa infections. Iran. Biomed. J. 17: 1–7. PMID:23279828.
22. Tavajjohi, Z., and Moniri, R. 2011. Detection of ESBLs and MDR in Pseudomonas aeruginosa in a tertiary-care teaching hospital. Iran. J. Clin. Infect. Dis. 6: 18–23.
23. Weimer, E.T., Lu, H., Kock, N.D., Wozniak, D.J., and Mizel, S.B. 2009. A fusion protein vaccine containing OprF epitope 8, OprI, and type A and B flagellins promotes enhanced clearance of nonmucoid Pseudomonas aeruginosa. Infect. Immun. 77: 2356–2366. doi:10.1128/IAI.00054-09. PMID:19349426.
24. Wolf, P., and Elsasser-Beile, U. 2009. Pseudomonas exotoxin A: from virulence factor to anti-cancer agent. Int. J. Med. Microbiol. 299: 161–176. doi:10.1016/j. ijmm.2008.08.003. PMID:18948059.